Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Medical Genetics

The Biology and Genetics of Thrombomodulin

At a Glance

THBD variants can change how thrombomodulin regulates clotting and the complement immune system. Some are linked to bleeding, while others may contribute to small-vessel clots; symptoms are not inevitable and may appear after triggers such as infection, pregnancy, or surgery.

Understanding the biology of a THBD mutation is like understanding a complex electrical circuit. The THBD gene provides the instructions for building a protein called thrombomodulin. This protein acts as a master switch on the surface of your blood vessels, and depending on how the instructions are “misspelled” (mutated), the switch can get stuck in the wrong position or break entirely [1][2].

The Master Switch: How it Normally Works

In a healthy body, thrombomodulin sits on the lining of your blood vessels (endothelium) and acts as a regulator for both your blood clotting system and your immune system (specifically the complement system) [3][4].

When a protein called thrombin—the body’s main tool for creating blood clots—comes near the vessel wall, thrombomodulin “grabs” it. This capture changes thrombin’s job completely [1]. Instead of building a clot, the captured thrombin activates two other proteins:

  • Protein C: This is your body’s natural “off-switch” for clotting. Once activated, it travels through the blood and stops new clots from forming [2].
  • TAFI: This protein helps stabilize existing clots so they don’t dissolve too quickly, ensuring a wound has time to heal [5][6].

Two Ways the Switch Can Break

Because this gene controls such a delicate balance, different types of mutations lead to the two “opposite” symptoms (bleeding or clotting) seen in this condition.

  • Some Reported Variants (Bleeding): Some specific variants (particularly certain truncating variants that alter membrane-anchoring) act like a “cut-off” command that stops the protein from being finished correctly. Instead of staying anchored to the blood vessel wall, the thrombomodulin breaks off and floats freely in the blood in massive amounts [7][8]. This “floating” thrombomodulin is hyper-active, flipping the clotting “off-switch” (Protein C) so constantly that the blood cannot clot when it needs to [7]. (Note that other truncating variants may lead to an absent or degraded transcript).
  • Other Reported Variants (Clotting/aHUS): Other variants, including some missense variants, are like a single typo in a long sentence. This typo may alter thrombin binding or complement regulation [9][10]. Without that regulation, the immune system (complement) can become overactive, leading to the small vessel clots seen in aHUS [4][10].

Inheritance and the “Second Hit”

This condition is typically autosomal dominant, meaning you only need to inherit one copy of the mutated gene from one parent to be at risk [7]. However, having the gene does not always mean you will have symptoms.

Doctors use the term incomplete penetrance to describe this [11]. You may carry the mutation your entire life without an issue. Depending on the variant and family history, a trigger—which could be a pregnancy, a major infection, or surgery—stresses the blood vessels and causes the underlying genetic vulnerability to finally show up as a clinical problem [4][12].

Understanding “VUS” (Variant of Uncertain Significance)

If you look at your genetic report, you may see your mutation labeled as a VUS or Variant of Uncertain Significance. This is a very common result for the THBD gene because the condition is so rare [10].

A VUS means that the lab found a change in your gene, but they do not yet have enough scientific data to prove whether that specific change is harmless or if it causes disease [10]. In a study of patients with these symptoms, every single one of the eight different THBD mutations found was initially classified as a VUS [10]. A VUS should not be used as proof of disease or as the basis for predictive testing and medical decisions in asymptomatic relatives. Always consult a genetic counselor or clinical geneticist to guide family testing and periodic laboratory reanalysis, using your personal and family history rather than just the genetic test alone [12].

Common questions in this guide

What does the THBD gene do in the body?
The THBD gene provides instructions for thrombomodulin, a protein on the lining of blood vessels. Thrombomodulin helps control clotting by changing thrombin’s activity, activating Protein C, and participating in regulation of the complement immune system.
How can a THBD variant lead to bleeding or clotting?
Some reported variants can release excess thrombomodulin into the blood, which may keep the natural clotting off-switch, Protein C, too active and contribute to bleeding. Other variants may impair thrombin binding or complement control, which can contribute to small-vessel clots and atypical hemolytic uremic syndrome.
Does inheriting a THBD variant mean I will develop symptoms?
No. This condition is usually autosomal dominant, so one altered copy can increase risk, but incomplete penetrance means some carriers never develop symptoms. Pregnancy, a major infection, or surgery may act as a trigger in some people.
What does a VUS in THBD mean on a genetic test?
A variant of uncertain significance, or VUS, is a THBD change that has not been studied enough to determine whether it is harmless or disease-causing. A VUS alone should not be used to diagnose the condition, guide predictive testing in symptom-free relatives, or make major medical decisions.
What should I do if my THBD result is a VUS?
Discuss the result with a genetic counselor or clinical geneticist, who can review your symptoms, family history, and other laboratory information. The laboratory may reanalyze the result as scientific knowledge grows, but testing and care should not rely on the VUS alone.
Can family members be tested for a THBD variant?
Family testing depends on whether the variant is known to cause disease and on the family’s medical history. A genetic counselor or clinical geneticist can explain which relatives might benefit from testing; a VUS generally should not be used for predictive testing in relatives without symptoms.

Get notified when new evidence is published on Familial thrombomodulin anomalies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence.

    Giri H, Biswas I, Rezaie AR

    Journal of thrombosis and haemostasis : JTH 2024; (22(4)):905-914 doi:10.1016/j.jtha.2024.01.006.

    PMID: 38266676
  2. 2

    Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation.

    Suzuki K

    Proceedings of the Japan Academy. Series B, Physical and biological sciences 2025; (101(2)):75-97 doi:10.2183/pjab.101.006.

    PMID: 39694492
  3. 3

    Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

    Sartain SE, Turner NA, Moake JL

    The Journal of biological chemistry 2018; (293(19)):7195-7208 doi:10.1074/jbc.RA118.002639.

    PMID: 29555686
  4. 4

    TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.

    Sartain SE, Turner NA, Moake JL

    Journal of immunology (Baltimore, Md. : 1950) 2016; (196(2)):832-45 doi:10.4049/jimmunol.1500960.

    PMID: 26673143
  5. 5

    Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis.

    Mochizuki L, Sano H, Honkura N, et al.

    Thrombosis and haemostasis 2023; (123(1)):16-26 doi:10.1055/s-0042-1757407.

    PMID: 36307100
  6. 6

    Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.

    Wu C, Stafford AR, Fredenburgh JC, et al.

    Thrombosis and haemostasis 2017; (117(8)):1509-1517 doi:10.1160/TH17-01-0054.

    PMID: 28640323
  7. 7

    A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.

    Westbury SK, Whyte CS, Stephens J, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.

    PMID: 32634856
  8. 8

    Whole exome sequencing identifies a mutation in thrombomodulin as the genetic cause of a suspected platelet disorder in a family with normal platelet function.

    Maclachlan A, Dolan G, Grimley C, et al.

    Platelets 2017; (28(6)):611-613 doi:10.1080/09537104.2017.1283011.

    PMID: 28267383
  9. 9

    Thrombomodulin Gly430Ser mutation attenuates the affinity with thrombin and contributes to thrombosis development.

    Chen N, Lai Z, Yuan J, et al.

    Journal of thrombosis and thrombolysis 2026; doi:10.1007/s11239-026-03379-0.

    PMID: 42521976
  10. 10

    Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis.

    Van Laer C, Lavend'homme R, Baert S, et al.

    Blood 2025; (145(17)):1929-1942 doi:10.1182/blood.2024026454.

    PMID: 39841007
  11. 11

    Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.

    Bu F, Zhang Y, Wang K, et al.

    Journal of the American Society of Nephrology : JASN 2018; (29(12)):2809-2819 doi:10.1681/ASN.2018070759.

    PMID: 30377230
  12. 12

    Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome.

    Schönauer R, Seidel A, Grohmann M, et al.

    Frontiers in genetics 2019; (10()):465 doi:10.3389/fgene.2019.00465.

    PMID: 31156713

This page is for informational purposes only and does not constitute medical advice about a THBD result or bleeding or clotting symptoms. A genetic counselor, clinical geneticist, or treating clinician should interpret your variant and guide family testing.